• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Finance

Finance

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101

January 24, 2023 Microbiome Times

Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value […]

Editor's Choice

Microbiome Drug Development: 2022 in Review

December 30, 2022 Luis Gosálbez

Leveraging a year of important research updates, funding rounds, and academic papers, this report compiles the most significant industry news pertaining to microbiome drug development in 2022. It finds that the regulatory approval of three […]

Finance

Biomica Raises $20 Million to Advance its Pipeline of Microbiome-based Therapeutics

December 22, 2022 Microbiome Times

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round, to […]

Finance

Beiersdorf acquires S-Biomedic and strengthens expertise in the field of acne treatment

December 16, 2022 Microbiome Times

Beiersdorf AG announced today that it has acquired a majority stake in S-Biomedic NV, Belgium, a life-science company and frontrunner in the field of skin microbiome research. Beiersdorf recognized the potential of the skin microbiome […]

Finance

A Biosolutions Juggernaut: Novozymes and Chr. Hansen to merge into one corporation

December 13, 2022 Microbiome Times

On December 12th, Novozymes and Chr. Hansen, two of the world’s leading biosolutions corporations, entered into an agreement to merge into a novel company. Prompted by global megatrends, including climate considerations, food system security, and […]

Editor's Choice

FDA Approves First Fecal Microbiota Product

December 1, 2022 Microbiome Times

Today, the U.S. Food and Drug Administration approved Rebyota, the first fecal microbiota product approved by the agency. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years […]

Finance

Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences

November 30, 2022 Microbiome Times

BRISBANE, Australia – Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) (“Sonic”) has agreed to invest $17.8m to acquire a […]

Finance

Holobiome Acquires Microbiome Startup AsiaBiome

November 25, 2022 Microbiome Times

Holobiome and AsiaBiome announce that they have closed a transaction for the acquisition of AsiaBiome by Holobiome. This acquisition unites two innovative life sciences companies that are committed to finding solutions to promote health through […]

Finance

Key patent issued on Eligo’s gene editing breakthroughs applied to skin disorders

November 16, 2022 Microbiome Times

Eligo Bioscience announced the issuance by the US Patent and Trademark Office (USPTO) of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support therapeutic […]

Finance

BiomeBank announces regulatory approval for donor derived microbiome drug

November 9, 2022 Microbiome Times

BiomeBank today announced the first regulatory approval for a donor derived microbiome drug product worldwide. The Therapeutic Goods Administration (TGA) approved BiomeBank’s product for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile […]

Finance

SYNLAB and Microba expand strategic agreement on advanced gut microbiome test

November 7, 2022 Microbiome Times

SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic […]

Posts navigation

1 2 … 23 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • “Probiotics” Green-lit for market-usage by French Authorities
    January 25, 2023
  • Microbiome Drug Development: 2022 in Review
    December 30, 2022
  • Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals
    December 22, 2022
  • FDA Approves First Fecal Microbiota Product
    December 1, 2022
  • Proge Farm claims Europe’s first regulatory approval for a microbiome-based therapeutic
    November 29, 2022
sign up

Sign up to the Microbiome Times newsletter